Synlogic, Inc.

The pace of new financings seems to be picking up in 2024 after a decline in the fourth quarter of 2023 relative to the last quarter of 2022, but some drug developers still are struggling to raise new

The pace of IPOs in 2022 is far below the record-breaking number of first-time offerings in 2021, with the last initial public offering in the US by a biopharmaceutical company completed by Acrivon T

Upstream Bio has been actively developing its strategy of acquiring externally discovered drug candidates for immune-mediated diseases for some time, but the start-up officially launched on 2 June wi

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Roche Exits Gene Therapy Delivery Pact